Our medical, nursing and allied health clinicians are increasingly involved in research to improve the care of our patients. This is reflected in the breadth of our research publications.
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Ross, DM; Pagani, IS; Shanmuganathan, N; Kok, CH; Seymour, JF; Mills, AK; Filshie, RJ; Arthur, CK; Dang, P; Saunders, VA; Braley, J; Yong, AS; Yeung, DT; White, DL; Grigg, AP; Schwarer, AP; Branford, S; Hughes, TP
(2018), Leukemia, 2572-2579
Management of Pregnancy in Women With Chronic Myeloid Leukemia
Ross, DM; Burbury, KL; Grigg, AP; Hughes, TP; Seymour, JF
(2018), J. Clin. Oncol., 2657-+
How we manage Gaucher Disease in the era of choices
Revel-Vilk, S; Szer, J; Mehta, A; Zimran, A
(2018), Br. J. Haematol., 467-480
DOI: 10.1111/bjh.15402
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
Radivoyevitch, T; Dean, RM; Shaw, BE; Brazauskas, R; Tecca, HR; Molenaar, RJ; Battiwalla, M; Savani, BN; Flowers, MED; Cooke, KR; Hamilton, BK; Kalaycio, M; Maciejewski, JP; Ahmed, I; Akpek, G; Bajel, A; Buchbinder, D; Cahn, JY; D'Souza, A; Daly, A; DeFilipp, Z; Ganguly, S; Hamadani, M; Hayashi, RJ; Hematti, P; Inamoto, Y; Khera, N; Kindwall-Keller, T; Landau, H; Lazarus, H; Majhail, NS; Marks, DI; Olsson, RF; Seo, S; Steinberg, A; William, BM; Wirk, B; Yared, JA; Aljurf, M; Abidi, MH; Allewelt, H; Beitinjaneh, A; Cook, R; Cornell, RF; Fay, JW; Hale, G; Chakrabarty, JH; Jodele, S; Kasow, KA; Mahindra, A; Malone, AK; Popat, U; Rizzo, JD; Schouten, HC; Warwick, AB; Wood, WA; Sekeres, MA; Litzow, MR; Gale, RP; Hashmi, SK
(2018), Leuk. Res., 130-136
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine
Prabahran, A; Tacey, M; Fleming, S; Wei, A; Tate, C; Marlton, P; Wight, J; Grigg, A; Tuckfield, A; Szer, J; Ritchie, D; Chee, L
(2018), Eur. J. Haematol., 174-184
DOI: 10.1111/ejh.13089
Hemoglobinopathies in the Fetal Position
Pasricha, SR; Drakesmith, H
(2018), N. Engl. J. Med., 1675-1677
Reducing anaemia in low income countries: control of infection is essential
Pasricha, SR; Armitage, AE; Prentice, AM; Drakesmith, H
(2018), BMJ-British Medical Journal
DOI: 10.1136/bmj.k3165
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
Pardanani, A; Gotlib, J; Roberts, AW; Wadleigh, M; Sirhan, S; Kawashima, J; Maltzman, JA; Shao, L; Gupta, V; Tefferi, A
(2018), Leukemia, 1034-1037
DOI: 10.1038/leu.2017.330
Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand
Nivison-Smith, I; Milliken, S; Dodds, AJ; Gottlieb, D; Kwan, J; Ma, DDF; Shaw, PJ; Tran, S; Wilcox, L; Szer, J
(2018), Biol. Blood Marrow Transplant., 169-174
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
Lim, ABM; Curley, C; Fong, CY; Bilmon, I; Beligaswatte, A; Purtill, D; Getta, B; Johnston, AM; Armytage, T; Collins, M; Mason, K; Fielding, K; Greenwood, M; Gibson, J; Hertzberg, M; Wright, M; Lewis, I; Moore, J; Curtis, D; Szer, J; Kennedy, G; Ritchie, D
(2018), Intern. Med. J., 276-285
DOI: 10.1111/imj.13522
Classifying the additional morbidities of Gaucher disease
Langeveld, M; Elstein, D; Szer, J; Hollak, CEM; Zimran, A
(2018), Blood Cells Mol. Dis., 209-+
Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease. Possible impact of reporting experience
Lai, JKC; Robertson, PL; Goh, C; Szer, J
(2018), Blood Cells Mol. Dis., 121-125
Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation
Kelly, DL; Buchbinder, D; Duarte, RF; Auletta, JJ; Bhatt, N; Byrne, M; DeFilipp, Z; Gabriel, M; Mahindra, A; Norkin, M; Schoemans, H; Shah, AJ; Ahmed, I; Atsuta, Y; Basak, GW; Beattie, S; Bhella, S; Bredeson, C; Bunin, N; Dalal, J; Daly, A; Gajewski, J; Gale, RP; Galvin, J; Hamadani, M; Hayashi, RJ; Adekola, K; Law, J; Lee, CJ; Liesveld, J; Malone, AK; Nagler, A; Naik, S; Nishihori, T; Parsons, SK; Scherwath, A; Schofield, HL; Soiffer, R; Szer, J; Twist, I; Warwick, A; Wirk, BM; Yi, J; Battiwalla, M; Flowers, ME; Savani, B; Shaw, BE
(2018), Biol. Blood Marrow Transplant., 228-241
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
Kantarjian, HM; Fenaux, P; Sekeres, MA; Szer, J; Platzbecker, U; Kuendgen, A; Gaidano, G; Wiktor-Jedrzejczak, W; Carpenter, N; Mehta, B; Franklin, J; Giagounidis, A
(2018), Lancet Haematol., E117-E126
Changing role of bone marrow examination in the diagnosis of hematological malignancies
Juneja, S; Westerman, D
(2018), Leuk. Lymphoma, 2018-2020
Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development
Ishay, Y; Zimran, A; Szer, J; Dinur, T; Ilana, Y; Arkadir, D
(2018), Blood Cells Mol. Dis., 117-120
Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
Hill, BT; Ahn, KW; Hu, ZH; Aljurf, M; Beitinjaneh, A; Cahn, JY; Cerny, J; Kharfan-Dabaja, MA; Ganguly, S; Ghosh, N; Grunwald, MR; Inamoto, Y; Kindwall-Keller, T; Nishihori, T; Olsson, RF; Saad, A; Seftel, M; Seo, S; Szer, J; Tallman, M; Ustun, C; Wiernik, PH; Maziarz, RT; Kalaycio, M; Alyea, E; Popat, U; Sobecks, R; Saber, W
(2018), Biol. Blood Marrow Transplant., 581-586
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Hiddemann, W; Barbui, AM; Canales, MA; Cannell, PK; Collins, GP; Durig, J; Forstpointner, R; Herold, M; Hertzberg, M; Klanova, M; Radford, J; Seymour, JF; Tobinai, K; Trotman, J; Burciu, A; Fingerle-Rowson, G; Wolbers, M; Nielsen, T; Marcus, RE
(2018), J. Clin. Oncol., 2395-+
Activating killer-cell immunoglobulin-like receptor haplotype influences clinical outcome following HLA-matched sibling haematopoietic stem cell transplantation
Heatley, SL; Mullighan, CG; Doherty, K; Danner, S; O'Connor, GM; Hahn, U; Szer, J; Schwarer, A; Bradstock, K; Sullivan, LC; Bardy, PG; Brooks, AG
(2018), HLA, 74-82
DOI: 10.1111/tan.13327
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Hallek, M; Cheson, BD; Catovsky, D; Caligaris-Cappio, F; Dighiero, G; Dohner, H; Hillmen, P; Keating, M; Montserrat, E; Chiorazzi, N; Stilgenbauer, S; Rai, KR; Byrd, JC; Eichhorst, B; O'Brien, S; Robak, T; Seymour, JF; Kipps, TJ
(2018), Blood, 2745-2760
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Dohner, H; Dolnik, A; Tang, L; Seymour, JF; Minden, MD; Stone, RM; del Castillo, TB; Al-Ali, HK; Santini, V; Vyas, P; Beach, CL; MacBeth, KJ; Skikne, BS; Songer, S; Tu, N; Bullinger, L; Dombret, H
(2018), Leukemia, 2546-2557
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
Dickinson, M; Cherif, H; Fenaux, P; Mittelman, M; Verma, A; Portella, MSO; Burgess, P; Ramos, PM; Choi, J; Platzbecker, U
(2018), Blood, 2629-2638
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma
Davids, MS; von Keudell, G; Portell, CA; Cohen, JB; Fisher, DC; Foss, F; Roberts, AW; Seymour, JF; Humerickhouse, RA; Tam, CS
(2018), J. Clin. Oncol., 3525-+
DOI: 10.1200/JCO.18.00359
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Davids, MS; Hallek, M; Wierda, W; Roberts, AW; Stilgenbauer, S; Jones, JA; Gerecitano, JF; Kim, SY; Potluri, J; Busman, T; Best, A; Verdugo, ME; Cerri, E; Desai, M; Hillmen, P; Seymour, JF
(2018), Clin. Cancer Res., 4371-4379
Characterization of Tfrc-mutant mice with microcytic phenotypes
Conway, AJ; Brown, FC; Rank, G; Kile, BT; Morton, CJ; Jane, SM; Curtis, DJ
(2018), Blood Adv., 1914-1922
Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline
Compernolle, V; Chou, ST; Tanael, S; Savage, W; Howard, J; Josephson, CD; Odame, I; Hogan, C; Denomme, G; Shehata, N
(2018), Transfusion, 1555-1566
DOI: 10.1111/trf.14611
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
Coleman, RE; Collinson, M; Gregory, W; Marshall, H; Bell, R; Dodwell, D; Keane, M; Gil, M; Barrett-Lee, P; Ritchie, D; Bowman, A; Liversedge, V; De Boer, RH; Passos-Coelho, JL; O'Reilly, S; Bertelli, G; Joffe, J; Brown, JE; Wilson, C; Tercero, JC; Jean-Mairet, J; Gomis, R; Cameron, D
(2018), J. Bone Oncol., 123-135
Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis
Chua, CC; Omerod, A; Wight, J; Juneja, S; Zantomio, D
(2018), Pathology, 671-674
Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma
Chua, CC; Lim, HY; Chai, KL; Ong, J; Sim, S; Wood, C; Dickinson, M; Campbell, P; Hempton, J; King, H; Dowsing, C; Bergin, K; Muir, S; Gibbs, S; Grigg, A
(2018), Bone Marrow Transplant., 1116-1123
The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable
Chin-Lenn, L; De Boer, RH; Segelov, E; Marx, GM; Hughes, TM; McCarthy, NJ; White, SC; Foo, SS; Rutovitz, JJ; Della-Fiorentina, S; Jennens, R; Antill, YC; Tsoi, D; Cronk, MF; Lombard, JM; Kiely, BE; Chirgwin, JH; Gorelik, A; Mann, GB
(2018), Asia-Pac. J. Clin. Oncol., 410-416
DOI: 10.1111/ajco.13075